Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test could spot dangerous prostate cancer without a biopsy

NCT ID NCT07492927

Diagnosis Sponsor: Xijing Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new blood test that looks for genetic material from tiny particles called exosomes to diagnose aggressive prostate cancer. The goal is to see if this test can accurately identify men who need a biopsy, avoiding unnecessary procedures. Researchers plan to enroll 1700 men with elevated PSA or other signs of prostate cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
plasma exosome RNA panel (blood test)
What this could lead to
If successful, this blood test could provide a non-invasive way to diagnose aggressive prostate cancer, potentially reducing the need for invasive biopsies.
What could go wrong
This is a diagnostic study, not a treatment. The test may not be accurate enough to replace current methods, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,700 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2021

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The men with suspected prostate cancer

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Blood prostate-specific antigen PSA\>4ng/dl; 2. Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging. 3. The patient is willing to undergo prostate biopsy. Exclusion Criteria: 1. Previous diagnosis of prostate cancer through prostate biopsy; 2. History of other malignant tumors in the past two years; 3. According to the research physician''s judgment, serious complications may occur and affect the normal conduct of the experiment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clinically significant prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clinically significant prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • General Hospital of Ningxia Medical University

    RECRUITING

    Yinchuan, Ningxia, China

  • Northwestern Memorial Hospital

    RECRUITING

    Chicago, Illinois, 60611, United States

  • Qinghai University Affiliated Hospital

    RECRUITING

    Xining, Qinghai, China

  • Shaanxi Provincial People's Hospital

    RECRUITING

    Xi'an, Shaanxi, China

  • The First Hospital of Lanzhou University

    RECRUITING

    Lanzhou, Gansu, China

  • The Second Affiliated Hospital of Shaanxi University of Chinese Medicine

    RECRUITING

    Xianyang, Shaanxi, China

  • Weinan Central Hospital

    RECRUITING

    Weinan, Shaanxi, China

  • Xijing 986 Hospital

    RECRUITING

    Xi'an, Shaanxi, China

  • Xijing Hospital

    RECRUITING

    Xi'an, 710032, China

  • Yan'an University Affiliated Hospital

    RECRUITING

    Yan’an, Shaanxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.